Harvard Medical School Researcher Publishes Favorable Study on Fisher Wallace Cranial Stimulator
NEW YORK, April 12 /PRNewswire/ — Fisher Wallace Laboratories today announced the results of a brain stimulation study involving the Fisher Wallace Cranial Stimulator, a portable medical device that treats depression, anxiety and insomnia. The study, published in The Neuroscientist and authored by Dr. Felipe Fregni, assistant professor in neurology at Harvard Medical School, analyzes a decade’s worth of research on the brain stimulation technology used by the Fisher Wallace Cranial Stimulator.
Included in the analysis is a 2006 study by Fregni in which patients who received non-invasive brain stimulation scored lower on tests for depression versus patients who were treated with a placebo device.
Fregni states, “The Fisher Wallace Cranial Stimulator decreases the level of neuronal activity in the motor cortex, a strong indication of why the device may be effective in some conditions with high cortical activity levels such as anxiety.”
Charles Avery Fisher, president of Fisher Wallace Laboratories, states, “Top psychiatrists such as Dr. Richard Brown and Dr. Andres San Martin at Columbia University have reported an 80 percent success rate using the device to treat depression, anxiety and insomnia in over 270 patients. Dr. Fregni’s paper now adds to the body of science that supports these extraordinary results.”
To view the study, visit: http://www.fisherwallace.com/uploads/Harvard_Medical_School_Research.pdf
On the market since 1991, the Fisher Wallace Cranial Stimulator is a handheld, FDA-sanctioned medical device that generates micro-currents of electricity using patented radio frequencies to stimulate the brain’s production of serotonin and dopamine. The device may be used at home on a daily basis and is safe for use by the elderly and children as young as two. A prescription is required to use the device in the U.S.
Other than a mild headache in one out of 450 patients, there are no negative side effects associated with using the Fisher Wallace Cranial Stimulator.
The device retails for $695, a fraction of the annual cost of pharmaceutical drugs that treat the same symptoms.
About Fisher Wallace Laboratories
Founded by Charles Avery Fisher, the son of stereo pioneer Avery Fisher, Fisher Wallace Laboratories manufactures the Fisher Wallace Cranial Stimulator, a cranial electrotherapy stimulation (CES) device sanctioned by the FDA for the treatment of depression, anxiety and insomnia. Today, Fisher Wallace Laboratories continues groundbreaking research at Harvard Medical School, Columbia Medical School, Massachusetts General Hospital, NYU Medical Center, University of Maryland, and the University of Medicine and Dentistry of New Jersey. The company’s devices are made in the USA.
SOURCE Fisher Wallace Laboratories